Physician profile
Farah E Nasraty
NPI 1104244813
$10,416.96
in general payments reported to CMS, 2019-2025
66 companies · $2,992 in 2025
The $2,992 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,827 · 2020: $1,281 · 2021: $554 · 2022: $1,078 · 2023: $1,355 · 2024: $1,330 · 2025: $2,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,558 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,558.43 |
| Education | $118.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $825.39 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Amgen INC. | $655.82 | 2019-2023 | Kyprolis, Blincyto |
| Alexion Pharmaceuticals, INC. | $583.15 | 2019-2025 | Ultomiris |
| Gilead Sciences, INC. | $544.58 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $535.48 | 2019-2025 | Keytruda, Lynparza |
| Incyte Corporation | $521.18 | 2019-2025 | Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $519.67 | 2019-2025 | |
| Pfizer INC. | $519.35 | 2020-2025 | |
| Abbvie INC. | $400.69 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $379.58 | 2019-2025 | |
| Sobi, INC | $305.77 | 2022-2025 | |
| Puma Biotechnology, INC. | $254.13 | 2019-2025 | |
| Genentech USA, INC. | $249.26 | 2019-2025 | Venclexta, Itovebi, Phesgo |
| Astellas Pharma US INC | $227.01 | 2019-2025 | Xospata, Vyloy |
| Karyopharm Therapeutics INC. | $226.77 | 2020-2025 | Xpovio |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $214.41 | 2019-2025 | |
| Seagen INC. | $207.23 | 2019-2023 | Tukysa |
| Celgene Corporation | $205.45 | 2019-2025 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $202.17 | 2020-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $182.53 | 2019-2024 | Rezlidhia, Tavalisse |
| Beigene USA, INC. | $176.72 | 2020-2024 | Brukinsa |
| Glaxosmithkline, LLC. | $166.74 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $161.51 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $146.79 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Aveo Pharmaceuticals, INC. | $129.32 | 2022-2025 | |
| Aurobindo Pharma USA, INC. | $124.99 | 2019 | |
| Tersera Therapeutics LLC | $122.36 | 2019-2025 | Zoladex |
| Foundation Medicine, INC. | $98.76 | 2019-2023 | |
| Janssen Biotech, INC. | $90.19 | 2021-2025 | Imbruvica, Darzalex, Rybrevant |
| Array Biopharma INC | $89.19 | 2020-2025 | Braftovi, Mektovi, Xalkori |
| Beone Medicines USA, INC. | $88.81 | 2025 | Brukinsa |
| Kite Pharma, INC. | $87.47 | 2020-2025 | Yescarta |
| Agios Pharmaceuticals, INC. | $71.79 | 2023-2025 | Pyrukynd |
| Ge Healthcare | $71.19 | 2025 | |
| Clovis Oncology, INC. | $66.59 | 2019-2020 | |
| Taiho Oncology, INC. | $64.05 | 2024 | |
| Emd Serono, INC. | $62.69 | 2021 | |
| Exelixis INC. | $54.85 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $52.34 | 2022-2025 | |
| Springworks Therapeutics, INC. | $49.12 | 2024-2025 | Ogsiveo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.72 | 2020-2025 | |
| Stemline Therapeutics INC. | $44.53 | 2025 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $44.21 | 2025 | |
| Blueprint Medicines Corporation | $43.65 | 2020-2023 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $38.93 | 2020-2021 | |
| Spectrum Pharmaceuticals INC. | $37.15 | 2019 | |
| Syndax Pharmaceuticals, INC. | $33.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $32.57 | 2022 | |
| Tesaro, INC. | $31.89 | 2019 | |
| Deciphera Pharmaceuticals INC. | $26.44 | 2024 | Qinlock |
| Adc Therapeutics America, INC. | $25.18 | 2025 | |
| Geron Corporation | $24.19 | 2025 | Rytelo |
| Csl Behring | $23.96 | 2025 | Afstyla, Idelvion |
| Fennec Pharmaceuticals, INC. | $22.53 | 2025 | Fyarro |
| Epizyme, INC. | $22.43 | 2020 | |
| Acceleron Pharma, INC. | $19.98 | 2020 | |
| Sumitomo Pharma America, INC. | $19.92 | 2025 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $19.35 | 2023 | Somatuline Depot, Onivyde |
| Mirati Therapeutics, INC. | $18.64 | 2023 | Krazati |
| Morphosys, US INC. | $18.35 | 2022 | |
| Novocure INC. | $18.20 | 2025 | Optune Lua (Novottf-200t) |
| Heron Therapeutics, INC. | $16.38 | 2019 | |
| Genmab U.S., INC. | $16.17 | 2023 | Epkinly |
| Alnylam Pharmaceuticals INC. | $15.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.67 | 2019 | |
| Secura Bio, INC. | $7.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Nasraty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.